Clinical Trial Detail


Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at :

NCT ID NCT03398655
Title A Study of VB-111 With Paclitaxel vs Paclitaxel for Treatment of Recurrent Platinum-Resistant Ovarian Cancer (OVAL) (OVAL)
Recruitment Completed
Gender female
Phase Phase III
Variant Requirements No
Sponsors Vascular Biogenics Ltd. operating as VBL Therapeutics
Age Groups: adult | senior
Covered Countries USA | ESP

No variant requirements are available.